TY - JOUR
T1 - Meta-analysis of the likelihood of FOXC1 expression in early-and late-stage tumors
AU - Kume, Tsutomu
AU - Shackour, Tarek
N1 - Funding Information:
This work was supported by the National Institutes of Health (NIH) (HL126920, EY028304, and HL144129 to T. K.). The authors thank W. Kevin Meisner, PhD, ELS, for editorial assistance.
Publisher Copyright:
© Kume et al.
PY - 2018/11/1
Y1 - 2018/11/1
N2 - Background: Aberrations in the expression of the transcription factor forkhead box C1 (FOXC1) have been linked to a number of malignancies. Here, we characterized the relationship between FOXC1 and cancer progression by conducting a meta-analysis of studies that reported the frequency of FOXC1 expression in tumors of different stages (T1, T2, T3, T4). Materials and Method: Relevant articles were retrieved from the Medline database by searching for the terms "FOXC1" and "cancer"; then, the retrieved articles were reviewed individually, and studies that were of multivariate cohort design, evaluated FOXC1 expression via immunohistochemical staining, and assessed the relationship between FOXC1 expression and cancer T-stage were included in our meta-analysis. Results: Our search terms identified 128 studies, 5 of which met all inclusion criteria. A total of 850 tumor samples were evaluated in the 5 studies; 452 samples were from early-stage (T1-T2) tumors, and 398 were from late-stage (T3-T4) tumors. FOXC1 was expressed in 60.7% (516/850) of all samples, in 54.6% (247/452) of early-stage tumor samples, and in 67.5% (269/398) of late-stage tumor samples. When calculated relative to early-stage samples, the pooled risk for FOXC1 expression in late-stage samples was 1.238 (95% CI = 1.061-1.444, p = 0.007). Conclusions: The results from our meta-analysis of 5 studies indicate that FOXC1 is 23.8% more likely to be expressed in late-stage tumors than in early-stage tumors.
AB - Background: Aberrations in the expression of the transcription factor forkhead box C1 (FOXC1) have been linked to a number of malignancies. Here, we characterized the relationship between FOXC1 and cancer progression by conducting a meta-analysis of studies that reported the frequency of FOXC1 expression in tumors of different stages (T1, T2, T3, T4). Materials and Method: Relevant articles were retrieved from the Medline database by searching for the terms "FOXC1" and "cancer"; then, the retrieved articles were reviewed individually, and studies that were of multivariate cohort design, evaluated FOXC1 expression via immunohistochemical staining, and assessed the relationship between FOXC1 expression and cancer T-stage were included in our meta-analysis. Results: Our search terms identified 128 studies, 5 of which met all inclusion criteria. A total of 850 tumor samples were evaluated in the 5 studies; 452 samples were from early-stage (T1-T2) tumors, and 398 were from late-stage (T3-T4) tumors. FOXC1 was expressed in 60.7% (516/850) of all samples, in 54.6% (247/452) of early-stage tumor samples, and in 67.5% (269/398) of late-stage tumor samples. When calculated relative to early-stage samples, the pooled risk for FOXC1 expression in late-stage samples was 1.238 (95% CI = 1.061-1.444, p = 0.007). Conclusions: The results from our meta-analysis of 5 studies indicate that FOXC1 is 23.8% more likely to be expressed in late-stage tumors than in early-stage tumors.
KW - Cancer
KW - FOXC1
KW - T-Stage
UR - http://www.scopus.com/inward/record.url?scp=85063339849&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85063339849&partnerID=8YFLogxK
M3 - Article
C2 - 30564302
AN - SCOPUS:85063339849
SN - 1949-2553
VL - 9
SP - 36625
EP - 36630
JO - Oncotarget
JF - Oncotarget
IS - 93
ER -
